A New Vaccination Method Based on Phage NgoΦ6 and Its Phagemid Derivatives

Andrzej Piekarowicz¹, Aneta Kłyż¹ and Daniel C. Stein²*

¹ Department of Virology, Faculty of Biology, Institute of Microbiology, University of Warsaw, Warsaw, Poland. ² Department of Cell Biology and Molecular Genetics, University of Maryland, College Park, College Park, MD, United States

Phagemid particles based on the Neisseria gonorrhoeae filamentous phage NgoΦ6 were used as a vaccine delivery system. We demonstrate that the host proteins incorporated into/associated with these particles can be encoded by chromosomal genes of the host bacterium or from plasmids able to replicate as an autonomous entity in the phagemid host. Phagemid particles were prepared from three types of cells, namely, Salmonella enterica ser. Typhimurium [pBSKS::Φ6fm(ST)] containing phagemid genome as an autonomous plasmid, Haemophilus influenzae Rd containing phagemid [pBSKS::Φ6fm(Hin)] integrated into the chromosome, and S. enterica ser. Typhimurium [pMPMT6::Φ6fm(ST)] containing an additional plasmid, pE1 HCV, encoding the Hepatitis C virus envelope glycoprotein E1. Approximately 200 µg of purified phage particles was used to immunize rabbits. The phagemid particles prepared from these three strains all elicited a large amount of IgG antibodies that were able to recognize bacterial host cells and proteins, as determined by ELISA and FACS analysis. The amount of specific anti-S. enterica, anti-H. influenzae, and anti-E1 HCV antibodies elicited by vaccination was 170 µg/ml for anti-Salmonella, 80 µg/ml for anti-H. influenzae, and 65 µg/ml for anti-E1 HCV. Taken in toto, these data suggest that classical phage display methods have underestimated the potential for filamentous phage as a novel immunogen delivery system.

Keywords: vaccine, phage display, filamentous phagemid display method without protein fusions, IgG induction, FACS analysis

INTRODUCTION

Bacteriophages have been used to make numerous contributions in the development of molecular biology and biotechnology, and in the development of vaccines. In molecular biology, phage display technology has been broadly used to study protein-protein interactions (Henry et al., 2015), library technology, immunotherapy (Hess and Jewell, 2020), antibody phage display technology
(Roth et al., 2021), and for general biomedical science applications (Alfaleh et al., 2020). Based on phages, vaccines are classified into three types, namely, phage DNA vaccines, phage display vaccines, and hybrid vaccines (Bao et al., 2019; Zalewska-Piatek and Piatek, 2021). Phage DNA vaccines contain an expression cassette of antigens or mimetics in the phage genome (González-Mora et al., 2020). Phage display vaccines consist of phages that display peptides or proteins fused to phage coat proteins with different peptides or proteins that are expressed as a single protein unit presented on the surface of the phage particle (Stern et al., 2019). The third type of vaccine is a combination of the two types mentioned earlier.

The broad application of phage display technology in the construction of vaccines encounters some difficulties and limitations [see reviews by Bao et al. (2019) and Zalewska-Piatek and Piatek (2021)]. Among them are the necessity of finding a peptide with the correct strong antigenic properties, limitations in the length of peptide that can be fused with the phage protein without influencing phage stability and infection properties, and loss of correct folding of phage protein, fused foreign peptide, or both. While existing phage display methods are based on the formation of a protein fusion between phage structural proteins and foreign peptides, we have developed a phage incorporation method (PhIM) that does not need the formation of protein fusions. This method is based on our previous publications that indicate the following: (1) phage NgoΦ6 can form phagemid particles from any Gram-negative bacterium where the phage genome is cloned into a plasmid that is able to replicate in that organism; (2) phagemid can be transferred into other bacteria by transformation (transfection) or by infection; (3) phagemid replicating in Gram-negative bacteria produce infective phagemid particles; (4) bacteria carrying such phagemid produce phagemid particles that show very strong antigenic properties and elicit antibodies against phage proteins without the use of any adjuvants; and (5) the viral particles of filamentous phages replicating in Neisseria gonorrhoeae and phagemids containing cloned NgoΦ6 genome into any type of plasmid contain not only phage-encoded proteins but also proteins encoded by bacterial genome and foreign genes (Piekarowicz et al., 2014, 2016; Kłyz and Piekarowicz, 2018). We showed that bacterial host proteins associated with the particle (as identified by mass spectrometry) tended to be one of the predominant outer membrane components of the host strain, plus minor additional host proteins (Piekarowicz et al., 2020). Examples of the proteins include PorB and Opa from N. gonorrhoeae, flagellin from S. enterica sv. Typhimurium, and OmpA from E. coli.

When NgoΦ6 was administrated orally by lysogenic cells of S. enterica ser. Typhimurium carrying phagemic pBS::Φ6fm or subcutaneously in the form of purified phage, sera obtained from vaccinated rabbits contained large amounts of IgG and IgA antibodies that were bound by N. gonorrhoeae cells and were able to kill the cells, presumably by binding to phages that were being extruded from the bacteria (Piekarowicz et al., 2016; Kłyz and Piekarowicz, 2018). Because the use of filamentous phage/phagemid particles in humans does not show apparent side effects, this indicates their safety. A clinical trial was recently approved by the FDA to allow for intravenous injection of phage to kill bacteria (LaFee and Buschman, 2020). Based on these findings and our previous publications demonstrating the association of host proteins with phage particles, we sought to determine if NgoΦ6 isolated from several bacteria could induce bactericidal responses against the immunizing strain.

**MATERIALS AND METHODS**

**Bacterial Strains, Plasmids, Phages, and Growth Conditions**

Salmonella enterica sv. Typhimurium χ3987 (Galan et al., 1990) obtained from Roy Curtiss III was grown in Luria-Bertani broth (LB) in the presence of diaminopimelic acid (DAP) (100 µg/ml final concentration), Escherichia coli Top10 was grown in LB broth, and H. influenzae was grown in brain heart infusion broth (BHI) (Difco) supplemented with hemin (10 µg/ml) and nicotinamide adenine dinucleotide (NAD) (2 µg/ml). All bacteria were incubated at 37°C with aeration. Isolation of S. enterica ser. Typhimurium, E. coli, and H. influenzae strains carrying pBSKS::Φ6fm (Hin) was described previously (Piekarowicz et al., 2016). S. enterica ser. Typhimurium 3872 (pMPMT6::Φ6fmST) carrying plasmid pE1-HCV [E1 protein (NC004102) virus MycD Tagged ORF clone Origene, United States] was obtained by introduction of the plasmid DNA by electroporation into E. coli Top10, purifying the plasmid, and then using the isolated plasmid to transform S. enterica ser. Typhimurium #3872 (pMPMT6::Φ6fmST). For convenience, phagemids propagated in E. coli are designated as pBSKS::Φ6fm(Ec), in S. enterica ser. Typhimurium as pBSKS::Φ6fm(ST), and in H. influenzae as pBSKS::Φ6fm(Hin).

**Enzymes and Chemicals**

DNA and protein size markers were purchased from Fisher Scientific (Vilno). All chemicals used were of reagent grade or better and were obtained from Sigma-Aldrich (St. Louis, MO, United States), unless otherwise noted. Hepatitis C virus E1 recombinant protein was obtained from ProSci (United States).

**Phage and Phagemid Particle Preparation**

To isolate phage and phagemid particles, overnight cultures were diluted 50-fold into 1,000 ml of an appropriate medium and grown overnight with shaking at 37°C. Bacteria were collected by centrifugation (20 min at ~6,000 RCF). The supernatant was mixed with 1/5 volume of a solution containing 20% polyethylene glycol (PEG-8000) and 2.5 M NaCl and kept at 4°C overnight to precipitate the phage particles. The precipitate was collected by centrifugation (20 min ~7,500 RCF), dissolved in 4 ml of phosphate-buffered saline (PBS), and centrifuged at 4,000 rpm in an SS34 rotor for 10 min. The phage particles were then purified by sequential centrifugation of the PBS phage suspension at ~2,000 RCF for 10 min and ~43,000 RCF for 120 min at 4°C. This procedure was repeated two times. The phagemid particles were further purified and quantified.
as described previously (Piekarowicz et al., 2020). Phagemid pBSKS::Φ6fm(ST) was additionally purified by CsCl gradient centrifugation as described by Sambrook and Russell (2001).

Production of Polyclonal Antisera

Samples of purified NgoΦ6 phagemid particles containing ~200 µg of protein were sent to EUROGENTEC S.A., Liege, Belgium, for immunization of three rabbits according to their standard protocol (ref. no AS-PNOR-3MORAB). In this protocol, phage suspensions were introduced two times subcutaneously at days 0 and 21 in each animal without any adjuvant. Sera were collected at day 0 (before immunization) and at days 21 and 28. To determine the activity, these sera were pooled. All animal work performed at the EUROGENTEC S.A., Liege, Belgium, was carried out in accordance with the 2010/63/EU directive on the protection of animals used for scientific purposes. The protocols were approved under reference CE/SANTE/E/001 by the CER ethical licensing committee.

Determination of Antibodies Against Phagemid Particles and E1 Protein of HCV Virus by Dot Spot ELISA

Determination of antibodies against phage particles was carried out as described previously (Piekarowicz et al., 2016) with modifications. Bacteria [3 µl of a suspension made of (2 × 10⁸ cells/ml)] diluted in PBS or 10 ng of EP1 protein (NC-004102) in carbonate buffer (50 mM sodium bicarbonate, 0.03 M sodium azide, pH 9.6) were spotted in triplicate onto a nitrocellulose membrane and dried at room temperature. After three washes with 20 ml of PBS buffer, the membranes were blocked with 1% alkaline casein (Sigma) in PBS at 25°C for 1 h. The membranes were then washed three times for 20 min with PBS. Following the washes, different dilutions of sera collected after 0 and 28 days in PBS with 1% alkaline casein were incubated at 25°C overnight. The membranes were washed three times with PBS and incubated with secondary antibodies at room temperature for 1 h [alkaline phosphatase-conjugated goat anti-rabbit IgG (Sigma-Aldrich, United States) diluted in PBS at 1:2,000]. The secondary antibody was removed, and the membranes were washed four times for 15 min each with PBS + 0.1% Tween-20 and once with PBS. Membranes were soaked in 20 ml of detection buffer (AP: 0.1 M Tris-HCl, pH 9.5; 0.1 M NaCl; 5 mM MgCl₂, pH 9.5) containing 20 µl of NBT BCIP for 30 min at room temperature in darkness. The reaction was stopped by washing the membrane with distilled water and dried. The following primary antibodies were used during studies: (1) (DYKDDDK) monoclonal antibodies (FG4R; Thermo Scientific), (2) monoclonal anti-E1 HCV protein (Clone BD198, OriGene), (3) antibodies obtained after subcutaneous vaccination with phagemid particles pBSKS::Φ6fm(ST), and (4) rabbit serum obtained after subcutaneous vaccination with phagemid particles pBSKS::Φ6fm(Hin), and (5) rabbit serum obtained after subcutaneous vaccination with phagemid particles pMPMT6::Φ6fm(ST) propagated in S. enterica ser. Typhimurium carrying plasmid encoding E1 HCV protein (all sera were used with 1:500 dilution). The following secondary antibodies were used: secondary mouse monoclonal 2A9 anti-rabbit IgG heavy chain (alkaline phosphatase; Abcam; 1:2,000 dilution); and secondary goat anti-mouse IgG H&L (alkaline phosphatase; Abcam; 1:4,000 dilution).

Flow Cytometric Analysis

Flow cytometry was performed according to Price et al. (2007) and described previously in detail (Piekarowicz et al., 2016).

Western Blotting

For Western blot analysis, proteins were transferred to a positively charged nylon membrane (Roche), blocked with 4% (w/v) non-fat milk in TBS at 25°C for 16 h, and then incubated with various antibodies suspended in TBS at 16°C overnight. After three washes with 20 ml of TBS buffer, the membranes were incubated with secondary antibodies at room temperature for 1 h. Secondary antibody was removed, and the membranes were washed four times for 5 min with TBS + 0.1% Tween-20 and once with TBS. Membranes were then soaked in 20 ml of detection buffer (AP: 0.1 M Tris-HCl, pH 9.5; 0.1 M NaCl; 5 mM MgCl₂, pH 9.5) containing 20 µl of NBT BCIP for 30 min at room temperature in darkness. The reaction was stopped by washing the membrane with distilled water and dried. The following primary antibodies were used: (1) (DYKDDDK) monoclonal antibodies (FG4R; Thermo Scientific), (2) monoclonal anti-E1 HCV protein (Clone BD198, OriGene), (3) antibodies obtained after subcutaneous vaccination with phagemid particles pBSKS::Φ6fm(ST), and (4) rabbit serum obtained after subcutaneous vaccination with phagemid particles pBSKS::Φ6fm(Hin), and (5) rabbit serum obtained after subcutaneous vaccination with phagemid particles pMPMT6::Φ6fm(ST) propagated in S. enterica ser. Typhimurium carrying plasmid encoding E1 HCV protein (all sera were used with 1:500 dilution). The following secondary antibodies were used: secondary mouse monoclonal 2A9 anti-rabbit IgG heavy chain (alkaline phosphatase; Abcam; 1:2,000 dilution); and secondary goat anti-mouse IgG H&L (alkaline phosphatase; Abcam; 1:4,000 dilution).

Transformation Protocols

Electrocompetent cells and transformation of Salmonella were carried out according to a procedure described previously (Sambrook and Russell, 2001) and stored at −80°C. Transformed bacteria were selected by plating onto LB agar plates containing appropriate antibiotics.

Statistical Analysis

All statistical analysis was carried out using Student’s t-test using Social Science Statistic web service. One-tailed P-values of < 0.05 were considered statistically significant.

---

1http://www.socstatistics.com
RESULTS

Host Proteins Associated With Phagemids pBSKS::Φ6fm(ST) Propagated in Salmonella enterica Ser. Typhimurium Elicit Antibodies Against Salmonella Cells

Our discovery that proteins other than phage filament proteins copurified with bacteriophage particles suggested that these particles could serve as a source of host-cell antigens (Piekarowicz et al., 2020). To test this possibility, we used phagemids propagated in (a) S. enterica ser. Typhimurium carrying pBSKS::Φ6fm plasmid, (b) H. influenzae Rd carrying pBSKS::Φ6fm phagemid integrated into bacterial chromosome, and (C) strain of S. enterica ser. Typhimurium carrying pMPMT6::Φ6 phagemid and plasmid pE1 HCV encoding Hepatitis C virus envelope glycoprotein E1. Approximately 200 µg of protein in the form of phage preparation was used to subcutaneously immunize rabbits without any adjuvant. Quantitative spot ELISA results used for the determination of levels of IgG antibodies specific for S. enterica ser. Typhimurium cells elicited by immunization of rabbits with purified pBSKS::Φ6fm(ST) showed significant levels of antibody induction (Figure 1). The above results showed that phagemid pBSKS::Φ6fm(ST) particles induce after subcutaneous delivery a strong immunological response and elicit a large amount of anti-Salmonella antibodies.

The binding activity was further analyzed by flow cytometry. The data in Figure 2B show a significant shift in the binding profile. Using the gating shown in the figure, 65% of the cell population bound significant levels of IgG present in immunized sera (Figure 2B), demonstrating that the elicited antibody was able to bind to intact cells. Preimmunized sera provided minimal binding (Figure 2A).

Host Proteins Associated With Phagemids pBSKS::Φ6fm(Hin) Elicit Antibodies Against Haemophilus influenzae Cells

The DNA sequence of pBSΦ6 is integrated into the chromosome of H. influenzae Rd30 cells (Piekarowicz et al., 2016). Lysogenic cells release phagemid particles that contain host cellular proteins (Piekarowicz et al., 2020). We used the same approach as described above to determine if these phagemid particles elicited antibodies against H. influenzae. Rabbit sera were obtained from animals immunized with purified pBSKS::Φ6fm(Hin) propagated in H. influenzae Rd30. Quantitative spot ELISA results again demonstrated significant levels of IgG antibodies specific for H. influenzae cells elicited by immunization of rabbits with purified pBSKS::Φ6fm(Hin) (Figure 3). Flow cytometry analysis (Figure 4) shows a significant shift in the binding profile, again demonstrating that the elicited antibody bound intact cells.
**Heterologous Association of Non-host Proteins in Phagemids**

We have previously shown that NgoPhi6 phagemid particles incorporate into/associate with the filament of not only phage structural proteins and host outer membrane proteins but also proteins produced by the expression of foreign genes (Piekarowicz et al., 2020). Purified pMPMT6::86fm phagemid particles grown in *S. enterica* ser. Typhimurium cells expressing the HCV E1 gene incorporate protein E1 into phagemid particles shown by the reactivity of this protein with anti-Myc DDK antibodies. Testing the presence of E1 HCV protein in these phagemid particles showed that the E1 protein is present not only as native 25 kDa protein but also as smaller degradation products. This was also observed for the presence of *Salmonella* flagella protein incorporated into pBSKS::86fm particles propagated in *Salmonella* cells (Piekarowicz et al., 2020). Purified phagemid pMPMT6::86fm particles grown in *S. enterica* ser. Typhimurium cells expressing the HCV E1 protein were used for the immunization of rabbits, and the elicited antibodies were tested for the reactivity with protein E1 HCV. The spot ELISA results used for the determination of levels of IgG-specific HCV E1 protein showed a very high level of antibodies (Figure 5).

**Quantification of Antibody Production**

The amount of antibody induced by various vaccine constructs was determined by comparing the optical density of specific anti-target protein antibodies bound to the spots of a standard curve obtained with known quantities of purified mouse IgG reference antibodies. Standard curves were prepared by the quantitative spot ELISA method. Since the measurement range of the ELISA dot was between dilution 2,000 and 5,000, the final determination of IgG concentration in all sera tested was based on the spot intensity values in this range. The amount of specific anti-*S. enterica* ser. Typhimurium, anti-*H. influenzae*, and anti-E1 HCV protein was 170 µg/ml for anti-*Salmonella*, 80 µg/ml for anti-*H. influenzae*, and 65 µg/ml for anti-E1 HCV protein.

**Elicited Antibodies Bind to Host Proteins Present in Bacterial Cells**

The data demonstrate that phagemid particles propagated in either *S. enterica* ser. Typhimurium, *H. influenzae*, or *S. enterica* sr. Typhimurium carrying pE1 plasmid encoding for HSV E1 protein in fact elicit a high level of IgG antibodies. To demonstrate that these antibodies bind to specific cellular proteins present in bacterial cells, several Western blots experiments were performed. We previously showed that flagellin proteins of 50 and 52 kDa molecular size or their degradation or precursor products are the predominant host proteins present in pBSKS::86fm(ST) particles (Piekarowicz et al., 2020). Western blotting was carried out to detect whether they represent also a majority of elicited antibodies in rabbits immunized subcutaneously with pBSKS::86fm(ST) phagemid particles. The data presented in Figure 6 show reactivity with several proteins, among them proteins in the 50 kDa range (Figure 6A, lane 1),...
when probed against *S. enterica* ser. Typhimurium cells without phagemids. The outer membrane protein P2 is a predominant host protein associated with pBS::Φ6fm(Hin) phagemid particles (Piekarowicz et al., 2020). Western blotting demonstrated that the phagemid isolated from pBS::Φ6fm(Hin) generated antibodies against both phagemid proteins and several host proteins, one with a mobility similar in mass to the P2 protein (molecular mass of ~37 kDa) (*Figure 6B*). Finally, Western blotting demonstrated that phagemids isolated from a strain that also expressed the HCV E1 protein-induced antibody were able to recognize this protein (*Figure 6C*). From these data, we concluded that phages derived from NgoΦ6 induce immune responses that reflect the host from which they were isolated.

## DISCUSSION

Filamentous phages were described and characterized in the 1960s (see Marvin and Hohn, 1969 for a topical review). Filamentous bacteriophages like NgoΦ6 are members of the genus *Inovirus* in the Inoviridae family. These thread-like viruses have a circular single-stranded DNA genome packaged into a fibrous structure with thousands of copies of coat proteins. During replication, a characteristic feature is that they do not lyse the host (see Hay and Lithgow, 2019 for a recent review). While filamentous phages are known to infect a wide variety of bacterial species (Roux et al., 2019), most of the work utilizing these phages has been based on those that infect *E. coli* (see Stern et al., 2019 for a recent review). This is largely based on the historical role of *E. coli* as a model organism for studying bacteria. The first molecular applications of these phages were for use as cloning vectors for DNA sequencing (Sanger et al., 1980). With the availability of well-developed tools and protocols for engineering phage, the replicative features of *E. coli* filamentous phage have more recently been exploited for use in phage display technology. The first demonstration of filamentous phage as an antigen delivery system was the construction of a fusion protein between the pIII minor coat protein of the bacteriophage f1 and the repeat regions of the circumsporozoite protein gene of *Plasmodium falciparum* (de la Cruz et al., 1988), but their usefulness as antigen delivery systems has largely been limited by the fact that these phages have been limited to the expression of short peptides (de Vries et al., 2021).

There are several dozen vaccines based on filamentous phages that are undergoing testing (see González-Mora et al., 2020 for a recent review), but most of these are anticancer vaccines or vaccines for the prevention of viral infections. This most likely is the result of the fact that fusion between phage structural proteins and peptides to be tested influences the frequency of formation of recombinant phages and their survival. Among all five structural genes of the *Inoviridae* used in phage display, gp3 is most frequently used, with gp6/gp7/gp9 much less (Jespers et al., 1995; Gao et al., 1999; Carmen and Jermutus, 2002; Ploss and Kuhn, 2011). Because of the complexity of bacterial cell surfaces, it is unlikely that epitope grafting would generate a protective response to these infections.

Our data suggest that the use of NgoΦ6 avoids these obstacles. First, it can be used in a broad spectrum of Gram-negative bacterial strains where phagemids based on phage NgoΦ6 can propagate. The majority of the proteins that we have identified that are incorporated into or associated with phage/phagemid particles belong to outer membrane proteins characterized by the presence of beta-barrel folds (Piekarowicz et al., 2020). While the foreign proteins not only retain their native length, they
can also undergo fragmentations, and such fragments are also incorporated (Piekarowicz et al., 2016). As the host proteins that are incorporated into/onto the phage particles are derived from the bacteria used for the propagation of phage, it eliminates the necessity of looking for immunogenic epitopes, increasing the chance that these proteins will retain their native conformation and will act as good antigens and good vaccines.

While the first antibodies produced after vaccination are IgMs, activated B cells subsequently undergo class switching to secrete IgG, among other isotypes. Hence, one hallmark of a good vaccine would be the induction of a strong IgG response. In most cases, increased levels of specific IgG antibodies correlate with increased immunity against the particular pathogen (Klimpel, 1996). Using 200 µg of purified phage/phagemid particles, we were able to generate a strong IgG response after a single boost. These antibodies were reactive with the host cells expressing the phage/phagemid. The data in Figure 6 clearly demonstrate that this response was able to recognize proteins other than those found in the phage genome. That this antibody was able to bind purified HCV protein (Figure 5) demonstrates that the observed reactivity was not due to simple contamination of host proteins with phagemid during the purification process. In toto, our data show that the protein incorporated into/onto phage particles can be derived from heterogeneous genetic elements (plasmids) present in these bacteria. This fact suggests using phagemid particles obtained from such bacteria in the construction of vaccines. Our example is the phagemid particles containing E1 protein of the HCV virus that was expressed from a plasmid.

Before this study can move forward, one needs to assess its limitations. We only immunized three animals and used pooled sera for all of our experiments. This precludes a statistical analysis of potential animal to animal variability. We have previously shown that the gene encoding Orf7 from Ngoθ6, while part of the phage filament, is dispensable (LaFee and Buschman, 2020). This unique property of Ngoθ6 suggests that any gene could replace this coding region, and it would be likely that the new gene would be incorporated into the phage. In this way, one could envision that Ngoθ6 could be used to deliver specific proteins encoded by Gram-positive bacteria or intact viral proteins, demonstrating that this could be a new platform for vaccine delivery. Because the phage particles can be generated from phagemids, it should be possible to engineer the phage so that it would lose its replicative abilities. However, it might be necessary to limit the presence of β-lactamase or other toxins or toxic proteins found in the host strain, requiring additional manipulation of that host. Modifications in the phage coat could be introduced, which alter the pharmacokinetics of bacteriophages or enhance antigen presentation. IgG antibodies play an important role as an element of immunological memory and therefore a role against reinfections by bacteria and viruses (Wu et al., 2016). In thinking how this filamentous phage can serve as a vaccine platform, one can think about the construction of strain producing phagemid particles in the bacterial strain containing both a phagemid genome and plasmids encoding one of three main membrane proteins of SARS-CoV-2 virus as a potential vaccine against COVID-19. Such a potential vaccine could be constructed very fast in an emergency situation.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the EUROGENETIC S.A. Liege Belgium.

AUTHOR CONTRIBUTIONS

AP: conceptualization, formal analysis, funding acquisition, investigation, methodology, project administration, supervision, validation, and writing – original draft. AK: formal analysis, investigation, methodology, validation, and writing – original draft. DS: conceptualization, funding acquisition, visualization, and writing – review and editing. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants to AP from the Polish Ministry of Science and Higher Education (Grant No. UMO-2014/13/B/NZ6/00245) and a grant to DS from the National Institutes of Health, AI (Grant No. AI099819).

REFERENCES

Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., et al. (2020). Phage display derived monoclonal antibodies: from bench to bedside. Front. Immunol. 11, 1986. doi: 10.3389/fimmu.2020.01986
Bao, Q., Li, X., Han, G., Zhu, Y., Mao, C., and Yang, M. (2019). Phage-based vaccines. Adv. Drug Delivery Rev. 145, 40–56.
Carmen, S., and Jermutus, L. (2002). Concepts in antibody phage display. Briefings Funct. Genomics Proteomics 1, 189–203. doi: 10.1093/bfgp/1.2.189
de la Cruz, V. F., Lal, A. A., and Mccutchan, T. F. (1988). Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J. Biol. Chem. 263, 4318–4322. doi: 10.1016/0021-9258(88)89276-6
de Vries, C. R., Chen, Q., Demirdjian, S., Kaber, G., Khosravi, A., Liu, D., et al. (2021). Phages in vaccine design and immunity; mechanisms and mysteries. Curr. Opin. Biotechnol. 68, 160–165. doi: 10.1016/j.copbio.2020.11.002
Galan, J. E., Nakayama, K., and Curtiss, R. III (1990). Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 94, 29–35. doi: 10.1016/0378-1119(90)90464-3
Gao, C., Mao, S., Lo, C. H., Wirsching, P., Lerner, R. A., and Janda, K. D. (1999). Making artificial antibodies: a format for phage display of combinatorial heterodimeric arrays. Proc. Natl. Acad. Sci. U.S.A. 96, 6025–6030. doi: 10.1073/pnas.96.11.6025
González-Mora, A., Hernández-Pérez, J., Iqbal, H. M. N., Rito-Palomes, M., and Benavides, J. (2020). Bacteriophage-based vaccines: a potent approach for antigen delivery. *Vaccines (Basel)* 8:504. doi: 10.3390/vaccines8030504

Hay, I. D., and Lithgow, T. (2019). Filamentous phages: masters of a microbial sharing economy. *EMBO Rep.* 20, e47427. doi: 10.15252/embr.201847427

Henry, K. A., Arbabi-Ghahroudi, M., and Scott, J. K. (2015). Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold. *Front. Microbiol.* 6:755. doi: 10.3389/fmicb.2015.00755

Hess, K. L., and Jewell, C. M. (2020). Phage display as a tool for vaccine and immunotherapy development. *Bioeng. Transl. Med.* 5:10142. doi: 10.1002/btm2.10142

Jespers, L. S., Messens, J. H., De Keyser, A., Eeckhout, D., Van Den Brande, I., Gansens, Y. G., et al. (1995). Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI. *Biotechnology* 13, 378–382. doi: 10.1038/nbt0495-378

Klimpel, G. (1996). “Immune defenses,” in *Baron* (Galveston, TX: University of Texas Medical Branch at Galveston).

Kłyź, A., and Piekarowicz, A. (2018). Phage proteins are expressed on the surface of *Neisseria gonorrhoeae* and are potential vaccine candidates. *PLoS One* 13:e0202437. doi: 10.1371/journal.pone.0202437

LaFee, S., and Buschman, H. (2020). With OK From FDA, UC San Diego Researchers Prepare to Launch Novel Phage Study. Clinical Trial Using Intravenous Viruses to Kill Resistant Bacteria Would Be First in Nation [https://Health.ucsd.edu/News/Releases/Pages/2019-01-08-Fda-Okays-Uc-San-Diego-To-Launch-Novel-Phage-Study.aspx (accessed August 25, 2021)].

Marvin, D. A., and Hohn, B. (1969). Filamentous bacterial viruses. *Bacteriol. Rev.* 33, 172–209. doi: 10.1128/b33.2.172-209.1969

Piekarowicz, A., Kłyź, A., Adamczyk-Poplawska, M., and Stein, D. C. (2020). Association of host proteins with the broad host range filamentous phage NgoPhi6 of *Neisseria gonorrhoeae*. *PLoS One* 15:e0240579. doi: 10.1371/journal.pone.0240579

Piekarowicz, A., Kłyź, A., Majchrzak, M., and Stein, D. C. (2016). Oral immunization of rabbits with *s. enterica* typhimurium expressing *Neisseria gonorrhoeae* filamentous phage g6 induces bactericidal antibodies against *N. gonorrhoeae*. *Sci. Rep.* 4:22549. doi: 10.1038/srep22549

Piekarowicz, A., Kłyź, A., Majchrzak, M., Szczesna, E., Piechucki, M., Kwiatek, A., et al. (2014). *Neisseria gonorrhoeae* filamentous phage NgoPhi6 is capable of infecting a variety of Gram-negative bacteria. *J. Virol.* 88, 1002–1010. doi: 10.1128/JVI.02707-13

Ploss, M., and Kuhn, A. (2011). Membrane insertion and assembly of epitope-tagged g9 at the tip of the M13 phage. *BMC Microbiol.* 11:211. doi: 10.1186/1471-2180-11-211

Price, G. A., Masri, H. P., Hollander, A. M., Russell, M. W., and Cornelissen, C. N. (2007). Gonococcal transferrin binding protein chimeras induce bactericidal and growth inhibitory antibodies in mice. *Vaccine* 25, 7247–7260. doi: 10.1016/j.vaccine.2007.07.038

Roth, K. D. R., Wenzel, E. V., Ruschig, M., Steinke, S., Langreder, N., Heine, P. A., et al. (2021). Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy. *Front. Cell Infect. Microbiol.* 11:697876. doi: 10.3389/fcimb.2021.697876

Roux, S., Krupovic, M., Daly, R. A., Borges, A. L., Nayfach, S., Schulz, F., et al. (2019). Cryptic inoviruses revealed as pervasive in bacteria and archaea across Earth’s biomes. *Nature microbiology* 4, 1895–1906. doi: 10.1038/s41564-019-0510-x

Sambrook, J., and Russell, D. W. (2001). Molecular Cloning: A Laboratory Manual, 3rd Edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.

Sanger, F., Coulson, A. R., Barrett, B. G., Smith, A. J., and Roe, B. A. (1980). Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. *J. Mol. Biol.* 143, 161–178. doi: 10.1016/0022-2836(80)90196-5

Stern, Z., Stylianou, D. C., and Kostrakis, L. G. (2019). The development of inovirus-associated vector vaccines using phage-display technologies. *Expert Rev. Vaccines* 18, 913–920. doi: 10.1080/14760584.2019.1651649

Wu, C.-H., Liu, I.-J., Lu, R.-M., and Wu, H.-C. (2016). Advancement and applications of peptide phage display technology in biomedical science. *J. Biomed. Sci.* 23:8. doi: 10.1186/s12929-016-0223-x

Zalewska-Piatek, B., and Piatek, R. (2021). Bacteriophages as potential tools for use in antimicrobial therapy and vaccine development. *Pharmaceuticals* 14:331. doi: 10.3390/ph14040331

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Piekarowicz, Kłyź and Stein.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.